Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). Cyxone’s technologies have the potential to address an unmet need to develop new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company’s development portfolio comprises Rabeximod in a clinical phase II program for RA and T20K that has successfully completed phase I infusion study for MS.